Fludarabine phosphate
- Product Name
- Fludarabine phosphate
- CAS No.
- 75607-67-9
- Chemical Name
- Fludarabine phosphate
- Synonyms
- FAMP;Fludura;F-ara-AMP;-F-ara-AMP;2-fluoro-araamp;5-Monophosphate;fludarabine hcl;fludara Phosphate;Fludarabin Phosphate;Fludarbine Phopshate
- CBNumber
- CB7347825
- Molecular Formula
- C10H13FN5O7P
- Formula Weight
- 365.21
- MOL File
- 75607-67-9.mol
Fludarabine phosphate Property
- Melting point:
- 203°C(dec.)(lit.)
- alpha
- [α]D20 +10～+14゜(c=0.5,H2O)
- Boiling point:
- 864.2±75.0 °C(Predicted)
- Density
- 2.39±0.1 g/cm3(Predicted)
- RTECS
- UO7440900
- storage temp.
- 2-8°C
- solubility
- DMSO: soluble1mg/mL
- form
- Powder
- pka
- 1.86±0.10(Predicted)
- color
- white
- Water Solubility
- Soluble in DMSO or water at 5mg/ml
- Merck
- 14,4126
- Stability:
- Hygroscopic
- InChIKey
- GIUYCYHIANZCFB-GFRUICAKSA-N
- CAS DataBase Reference
- 75607-67-9(CAS DataBase Reference)
Safety
- WGK Germany
- 3
- HS Code
- 2934990002
Hazard and Precautionary Statements (GHS)
- Symbol(GHS)
-
- Signal word
- Warning
- Hazard statements
-
H341Suspected of causing genetic defects
- Precautionary statements
-
P201Obtain special instructions before use.
P202Do not handle until all safety precautions have been read and understood.
P280Wear protective gloves/protective clothing/eye protection/face protection.
P308+P313IF exposed or concerned: Get medical advice/attention.
P405Store locked up.
P501Dispose of contents/container to..…
N-Bromosuccinimide Price
- Product number
- Y0002256
- Product name
- Fludarabine for peak identification
- Purity
- European Pharmacopoeia (EP) Reference Standard
- Packaging
- Y0002256
- Price
- $161
- Updated
- 2024/03/01
- Product number
- F9813
- Product name
- Fludarabine phosphate
- Packaging
- 5mg
- Price
- $78.2
- Updated
- 2024/03/01
- Product number
- 1272204
- Product name
- Fludarabine phosphate
- Packaging
- 300mg
- Price
- $436
- Updated
- 2024/03/01
- Product number
- F0913
- Product name
- Fludarabine Monophosphate
- Purity
- >98.0%(HPLC)(T)
- Packaging
- 25mg
- Price
- $30
- Updated
- 2024/03/01
- Product number
- F0913
- Product name
- Fludarabine Monophosphate
- Purity
- >98.0%(HPLC)(T)
- Packaging
- 100mg
- Price
- $84
- Updated
- 2024/03/01
Fludarabine phosphate Chemical Properties,Usage,Production
Description
Fludarabine phosphate is an antimetabolite indicated for the treatment of B cell lymphocytic leukemia. It is reportedly effective in patients refractory to other therapies. Fludarabine phosphate acts by inhibiting primer RNA synthesis. Its side effects include bone marrow suppression, anemia, thrombocytopenia and neutropenia.
Chemical Properties
White or almost white, crystalline powder, hygroscopic.
Originator
Southern Research Institute (U.S.A.)
Uses
Fludarabine phosphate is used for the treatment of chronic lymphatic leukemia and low-grade lymphoma. In the circulation,fludarabine phosphate is immediately dephosphorylated to the nucleoside fludarabine. About 30-40% of nucleoside fludarabine is excreted into the urine. In addition, fludarabine is metabolized into a hypoxanthine metabolite also excreted in the urine.Intracellularly,fludarabine is stepwise rephosphorylated to the active triphosphate. Deoxycytidine kinase is the dominant, if not the exclusive,enzyme for the formation of the monophosphate. Adenylate kinase and nucleoside diphosphate kinase are believed to be involved in the formation of the diphosphate and triphosphate,respectively.
Uses
anticonvulsant
Definition
ChEBI: Fludarabine phosphate is a purine arabinonucleoside monophosphate having 2-fluoroadenine as the nucleobase. A prodrug, it is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. Once incorporated into DNA, 2-fluoro-ara-ATP functions as a DNA chain terminator. It is used for the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to, or whose disease has progressed during, treatment with at least one standard alkylating-agent containing regimenas. It has a role as an antimetabolite, an antineoplastic agent, an immunosuppressive agent, an antiviral agent, a prodrug and a DNA synthesis inhibitor. It is an organofluorine compound, a nucleoside analogue and a purine arabinonucleoside monophosphate. It derives from a 2-fluoroadenine.
brand name
Fludara (Berlex), Benefluor (Schering AG).
Mechanism of action
Fludarabine phosphate is a cytotoxic purine antimetabolite that acts by inhibiting DNA synthesis. Fludarabine and its soluble derivatives interfere with phosphorylation, e.g., in L 1210 cells. Fludarabine behaves more like an analog of deoxycytidine than adenine or deoxyadenine as indicated by reports demonstrating that the presence of fluorine in the 2-position of the adenine ring alters its function as a substrate for deaminase and nucleoside kinases. This results in differences in biological activity and metabolism. Halogenation does not simply block deamination, but also influences the enzyme that carries out the phosphorylation, as a result cytotoxicity is increased. Fludarabine phosphate may selectively inhibit the incorporation of thymidine and uridine into the DNA molecule by inhibiting both ribonucleotide reductase and DNA polymerase. The maximum tolerated dose (MTD) in heavily pretreated patients with advanced malignancy/solid tumors on the daily regimen was about 15 mg/m2. Granulocytopenia and thrombocytopenia were dose-limiting.
Pharmacology
Fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite appears to act by inhibiting DNA polymerase alpha, ribonucleotide reductase and DNA primase, thus inhibiting DNA synthesis. The mechanism of action of this antimetabolite is not completely characterized and may be multi-faceted.
Phase I studies in humans have demonstrated that fludarabine phosphate is rapidly converted to the active metabolite, 2-fluoro-ara-A, within minutes after intravenous infusion.
Consequently, clinical pharmacology studies have focused on 2-fluoro-ara-A pharmacokinetics. After the five daily doses of 25 mg 2-fluoro-ara-AMP/m2 to cancer patients infused over 30 minutes, 2-fluoro-ara-A concentrations show a moderate accumulation. During a 5-day treatment schedule, 2-fluoro-ara-A plasma trough levels increased by a factor of about 2. The terminal half-life of 2-fluoro-ara-A was estimated as approximately 20 hours. In vitro, plasma protein binding of fludarabine ranged between 19% and 29%.
Clinical Use
Fludarabine phosphate (Fludara ® ), is a fluorinated nucleotide analog of the antiviral agent vidarabine, 9-β-D-arabinofuranosyladenine(ara-A), which differs only by the presence of a fluorine atom at position 2 of the purine moiety and a phosphate group at position 5 of the arabinose moiety (Plunkett et al., 1993). These structural modifications result in increased aqueous solubility and resistance to enzymatic degradation by adenosine deaminases compared to vidarabine (Brockman et al., 1977; Plunkett et al., 1990). Fludarabine phosphate is indicated for the treatment of patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating agent containing regimen (Boogaerts et al., 2001; Rossi et al., 2004).
target
DNA synthesis
Drug interactions
Potentially hazardous interactions with other drugs Antipsychotics: avoid concomitant use with clozapine, increased risk of agranulocytosis. Cytotoxics: increased pulmonary toxicity with pentostatin (unacceptably high incidence of fatalities); increases intracellular concentration of cytarabine.
Metabolism
Intravenous fludarabine phosphate is rapidly dephosphorylated to fludarabine which is taken up by lymphocytes and rephosphorylated via the enzyme deoxycytidine kinase to the active triphosphate nucleotide. Clearance of fludarabine from the plasma is triphasic; elimination is mostly via renal excretion: 40-60% of an intravenous dose is excreted in the urine. The pharmacokinetics of fludarabine show considerable inter-individual variation
Fludarabine phosphate Preparation Products And Raw materials
Raw materials
Preparation Products
Fludarabine phosphate Suppliers
- Tel
- 18036652731
- 2843986978@qq.com
- Country
- China
- ProdList
- 54
- Advantage
- 58
- Tel
- 027-84222527， 13774034449
- Fax
- 027-84222392
- zhoubo@biocause.net
- Country
- China
- ProdList
- 9
- Advantage
- 58
- Tel
- 0714-6352055 15897769779
- Fax
- 0714-6352055
- sales@healthdaychem.com
- Country
- China
- ProdList
- 95
- Advantage
- 55
- Tel
- 19852363252; 19852363252
- 2634809846@qq.com
- Country
- China
- ProdList
- 53
- Advantage
- 58
- Tel
- 0518-80639699 19852363252
- xutangyan@xdrpharm.com
- Country
- China
- ProdList
- 37
- Advantage
- 58
- Tel
- 023-68509220
- sales1@biolandpharm.com
- Country
- China
- ProdList
- 69
- Advantage
- 58
- Tel
- 020-87317062 13048089691
- 852378519@qq.com
- Country
- China
- ProdList
- 160
- Advantage
- 58
- Tel
- 021-50182298 021-50180596
- Fax
- +86-21-57758967
- sales@boylechem.com
- Country
- China
- ProdList
- 2208
- Advantage
- 55
- Tel
- 010-82848833 400-666-7788
- Fax
- 86-10-82849933
- jkinfo@jkchemical.com
- Country
- China
- ProdList
- 94657
- Advantage
- 76
- Tel
- +49 3493/605464
- Fax
- +49 3493/605470
- sales@intatrade.de
- Country
- Germany
- ProdList
- 3572
- Advantage
- 66
View Lastest Price from Fludarabine phosphate manufacturers
- Product
- Fludarabine phosphate 75607-67-9
- Price
- US $99.00-80.00/kg
- Min. Order
- 1kg
- Purity
- 99%
- Supply Ability
- 5000
- Release date
- 2024-08-21
- Product
- Fludarabine phosphate 75607-67-9
- Price
- US $0.00-0.00/KG
- Min. Order
- 1KG
- Purity
- EP, USP
- Supply Ability
- 100ton
- Release date
- 2024-09-14
- Product
- Fludarabine Phosphate 75607-67-9
- Price
- US $2.70/kg
- Min. Order
- 10kg
- Purity
- 99.7%
- Supply Ability
- 10000kg
- Release date
- 2024-08-20